LET’S STAY CONNECTED
[ctct form="2827" show_title="false"]
Copyright © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Privacy Policy.
The Most Trusted Source
For Autologous Exosomes
LEADERS IN THE DEVELOPMENT OF NEW TECHNOLOGIES IN BIOLOGIC MEDICINE
EXTRACELLULAR VESICLE THERAPEUTICS
Learn More
The Most Trusted Source For Autologous Exosomes
CLINICAL R&D PROGRAM UPDATES
Our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, has created a novel biologic candidate that represents the next frontier of regenerative medicine. Organicell™ is committed to creating life changing and lifesaving therapies for important clinical conditions.
OSTEOARTHRITIS (OA)
Organicell received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, for the treatment of knee osteoarthritis. We completed a Phase 1 study for knee osteoarthritis and established the safery of our exosome therapeutics. A double blinded, placebo-controlled, phase II trial investigating the safety and efficacy of Zofin™ for patients suffering with knee osteoarthritis is planned for 2024
Chronic Obstructive Pulmonary Disease (COPD)
Organicell received approval from the (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, in the treatment of patients diagnosed with COPD. This approved trial design will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of intravenous infusion (IV) of Zofin™ for the treatment of COPD.
COVID-19
Organicell has completed a Phase I in patients with moderate to severe COVID-19 as well as a separate Phase 1 study in patient with “long-haul” COVID-19. The FDA also granted the company an expanded access IND that provided additional patients with COVID-19 access to Zofin outside of the formal clinical trial. This expanded access protocol provides access to Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to be at high risk of progression to moderate disease. The trial is being conducted at the United Memorial Medical Center in Houston, TX.
Organicell is committed to completing our FDA-approved clinical trials as we hope to develop an FDA-approved treatment for multiple clinical conditions.
ORGANICELL™ BIOLOGICS
OUR MISSION
To pioneer the frontiers of medical science through rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies and nano-technologies to address a broad range of medical conditions.
ORGANICELL™ BIOLOGICS
OUR MISSION
To pioneer the frontiers of medical science through rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies and nano-technologies to address a broad range of medical conditions.
THE ORGANICELL™ DIFFERENCE
- Creating ultra-high concentration biologics containing hundreds of billions of extracellular vesicles (nanoparticles) per ml.
- PPX™ – a novel product of ultra-high concentration autologous nanoparticles (from a patient’s own blood)
- Isolating and concentration extracellular vesicles that contain over 300 bioactive agents including: miRNA, RNA, DNA, cytokines, lipid, metabolites, and proteins – that reduce inflammation and promote tissue regeneration.
- There is a tremendous therapeutic potential of extracellular vesicles and nano-particles.
- Zofin™ and PPX™ are not culture, expanded, and are not classified as an HCT/P
- Patent Pending Technology.
- Multiple ongoing Clinical Trials – with FDA approved INDs.
We Believe We Have Found The Key To Consistent
Patient Outcomes
THE ORGANICELL™ DIFFERENCE
- Creating ultra-high concentration biologics containing hundreds of billions of extracellular vesicles (nanoparticles) per ml.
- PPX™ – a novel product of ultra-high concentration autologous nanoparticles (from a patient’s own blood)
- Isolating and concentration extracellular vesicles that contain over 300 bioactive agents including: miRNA, RNA, DNA, cytokines, lipid, metabolites, and proteins – that reduce inflammation and promote tissue regeneration.
- There is a tremendous therapeutic potential of extracellular vesicles and nano-particles.
- Zofin™ and PPX™ are not culture, expanded, and are not classified as an HCT/P
- Patent Pending Technology.
- Multiple ongoing Clinical Trials – with FDA approved INDs.
We Believe We Have Found The Key To Consistent
Patient Outcomes